GSK (LSE:GSK) has declared a 17p third-quarter Dividend alongside results that beat expectations but also showed a sharp drop in total operating profit. The drugmaker's numbers therefore offer two readings, and income investors need to look at both. With the payout comfortably covered on the latest data, the dividend looks more secure than the headline profit fall alone would suggest.

Solid specialty sales, weaker total profit

GSK's third-quarter results, published on 28 October, showed sales up 5% to £8.9bn, with specialty medicines growing 15%. That strength helped to offset destocking of its Shingrix shingles Vaccine in China. The company reaffirmed its 2026 guidance, pointing to the upper half of its ranges, according to reports of the results call.

Core profit rose 5%, but a filing summary showed total operating profit down 16% at constant currencies, with a restructuring charge weighing on the statutory figure. Core numbers exclude such items and are the ones most analysts focus upon, while total results capture the actual charge taken. One report said that the shares fell in pre-market trading despite the results beating estimates, suggesting that the market reaction was not as straightforward as the headline.

What the dividend numbers say

The figures here come from a snapshot dated 7 October 2026, so the yields will have changed with the share price since then. The data showed an annual dividend of 66.0p per share and a latest quarterly payment of 17.0p, matching the newly declared 17p. The trailing 12-month Yield was 3.9% and the indicated yield was 4.0%.

The gap between those yields is easy to explain. The indicated measure looks ahead on the basis of the current payment rate, and four payments of 17p would come to 68p against the 66p annual figure in the data. That is simple arithmetic and not a company forecast, but it does illustrate the higher run rate.

The Payout Ratio stood at 56.8%, which means that Earnings covered the dividend about 1.8 times on a trailing basis. For a pharmaceutical group with heavy R&D spending, that level leaves meaningful headroom. It is also useful context for the latest restructuring charge, because a Business in this position has more room to absorb one-off costs than a company paying out most of its earnings.

A rebuilt record

Dividend per share rose 8.2% year on year, a solid increase and well above what many FTSE 100 income stocks have managed. GSK has paid dividends continuously for 41 years, which is a long record, but the figure for continuous growth is only two years.

That contrast is the more revealing statistic. A long payment history shows that shareholders have always received something, while the short growth streak shows that the amount has not always risen. The data does not itself explain the reason, and investors should not treat 41 years of payments as if it were 41 years of increases. The current pattern is of a company now growing its dividend from a reset base, with two years not yet long enough to count as an established trend.

Pharmaceutical income also depends on the pipeline in a way that a utility's does not. Today's specialty growth is encouraging, but vaccine Demand has proved more volatile, as the Shingrix destocking in China shows. Future dividend growth will depend on whether newer medicines can continue to outrun those pressures.

What to watch

Investors will be looking for fourth-quarter results to show whether GSK (LSE:GSK) lands in the upper half of its guidance as indicated, and for the full-year dividend total, which will show how far the 66p figure has moved. Further progress in specialty medicines, the course of Shingrix in China and any further restructuring costs will all be relevant to how much cover remains in place.